BLX Technology Integration
Integrated Roxolid® and SLActive® technologies into BLX and helped position the implant system within Straumann® ImmediaXy™ as a high-performance solution for immediate treatment protocols.
Back to portfolio
Case 07
Other examples: Product Innovation, Evidence and Regulatory Impact
A selection of additional cases — from creative and digital workflows to high-impact FDA regulatory milestones.
Straumann® ImmediaXy™ Ecosystem
Helped shape and position Straumann® ImmediaXy™ as an end-to-end ecosystem connecting data acquisition, treatment planning, surgery and restoration for efficient and predictable immediate treatment workflows.
Straumann® ProClean Cassette
Led cross-functional development of the Straumann® ProClean Cassette, translating the demanding requirements of major hospitals and Sterile Services Departments into a validated, high-spec solution for fully automated instrument reprocessing. The platform helped secure adoption across 45+ US VA hospitals and 4 Bundeswehr hospitals, opening substantial downstream implant business and contributing to 20% implant revenue growth.
SLActive® Evidence in Irradiated Patients
Recognised a critical interpretation barrier in long-term SLActive® evidence for head and neck irradiated cancer patients and engaged Prof. Nelson to develop a clinical clarification. Aligned Clinical, Medical and Regulatory Affairs teams around the evidence and used the resulting publication as a key submission document supporting the removal of IFU restrictions and enabling predictable implant-supported prosthetic rehabilitation for this high-risk population.
Compromised Patients: FDA Regulatory Milestone
Established medically compromised patients as a strategic evidence and differentiation platform for SLActive®, leading the evidence roadmap and aligning Clinical, Medical and Regulatory Affairs around patients with Type II diabetes and those previously irradiated in the head and neck. The programme culminated in a major Regulatory Affairs milestone: FDA-cleared removal of both populations from IFU cautions and precautions, creating a unique regulatory position for Straumann and addressing significant unmet needs — including predictable implant-supported rehabilitation following oral cancer.